2403P LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
Jonathan Zarka, Donald S. Childs(Mayo Clinic), Irbaz Bin Riaz(Mayo Clinic), Oliver Sartor(Mayo Clinic), Praful Ravi(Dana-Farber Cancer Institute), Adam M. Kase(Jacksonville College), Yael Kusne(WinnMed), Syed Arsalan Ahmed Naqvi(Mayo Clinic Hospital), Mrinal M. Patnaik(Mayo Clinic), E. Heath(The Barbara Ann Karmanos Cancer Institute), Ronit Juthani(Dana-Farber Cancer Institute), Jacob J. Orme(Mayo Clinic), M. Muniz(Mayo Clinic), H. Jacene(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
|The Lancet Respiratory Medicine|2021|257
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
|Haematologica|2019|215
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
|Journal of Clinical Investigation|2018|209